Publications by authors named "A Britton"
Article Synopsis
- A study was conducted from September 2022 to April 2023 to evaluate how COVID-19 vaccines affect the risk of infection in children under 5 years old.
- The results showed no significant difference in infection risk between vaccinated and unvaccinated children.
- Although the vaccines are effective in preventing severe illness, they may not prevent the actual infection of the virus in young kids.
Midlife heart rate variability and cognitive decline: A large longitudinal cohort study.
Int J Clin Health Psychol
November 2024
Background: Autonomic dysfunction is common in dementia, yet its contribution to neurocognitive changes remains unknown. We investigated whether midlife cardiac vagal modulation, indexed by heart rate variability, associates with subsequent cognitive decline in adults without prior coronary heart disease or stroke.
Methods: The sample comprised 2702 (1924 men) individuals initially aged 44-69 years from the UK Whitehall II cohort.
Prognostic Significance and Associations of Neural Network-Derived Electrocardiographic Features.
Circ Cardiovasc Qual Outcomes
December 2024
Article Synopsis
- The study explores the use of advanced neural network-derived ECG features to predict cardiovascular disease and mortality, aiming to uncover subtle, important indicators that traditional methods might miss.
- Using data from over 1.8 million patients and various international cohorts, researchers identified three distinct phenogroups, with one, phenogroup B, showing a significantly higher mortality risk—20% more than phenogroup A.
- The findings suggest that neural network ECG features not only indicate future health risks like atrial fibrillation and ischemic heart disease but also highlight specific genetic loci that may contribute to these risks.
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection-Increasing Community Access to Testing Program, United States, January-September 2023.
Influenza Other Respir Viruses
November 2024
Background: On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.
Methods: Using national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case-control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.
Results: VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%-52%) for those aged ≥ 65 years to 61% (95% CI 41%-75%) for those aged 12-17 years.